Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Affinity and Avidity01:41

Affinity and Avidity

Overview
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2025
Same author

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.

Blood·2025
Same author

[The Free Functional Latissimus dorsi Flap for the Reconstruction of Complex Abdominal Wall Defects: Anatomy, Technique and Approach for Interdisciplinary Treatment].

Zentralblatt fur Chirurgie·2025
Same author

Mice with a diverse human T cell receptor repertoire selected on multiple HLA class I molecules.

Nature communications·2025
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

It's the peptide-MHC affinity, stupid.

Thomas Kammertoens1, Thomas Blankenstein

  • 1Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany.

Cancer Cell
|April 20, 2013
PubMed
Summary
This summary is machine-generated.

Adoptive T cell therapy can eliminate large tumors, but cancer recurrence is common. T cell receptor affinity for the peptide-MHC complex dictates if tumors will relapse after this cancer treatment.

More Related Videos

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

Related Experiment Videos

Last Updated: May 12, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Adoptive T cell therapy (ACT) shows promise for treating established tumors.
  • Tumor recurrence after ACT is often driven by tumor escape variants.
  • Understanding factors influencing ACT efficacy is crucial for improving patient outcomes.

Discussion:

  • Engels et al. investigated the role of peptide-MHC affinity in T cell-mediated tumor rejection.
  • High-affinity interactions between T cell receptors and target peptide-MHC complexes are critical for sustained tumor control.
  • Low-affinity interactions may lead to T cell exhaustion and tumor relapse.

Key Insights:

  • Peptide-MHC affinity is a key determinant of therapeutic success in ACT for large tumors.
  • Optimizing T cell affinity for tumor antigens could enhance the durability of ACT responses.
  • This finding has implications for designing more effective T cell-based cancer immunotherapies.

Outlook:

  • Further research should explore strategies to enhance T cell affinity or overcome low-affinity interactions.
  • Clinical translation of affinity-optimized T cells could improve treatment outcomes for various cancers.
  • Developing predictive biomarkers for ACT response based on peptide-MHC affinity is warranted.